Your session is about to expire
← Back to Search
Olaparib for Ovarian Cancer
Study Summary
This trial is testing a new combination of drugs to treat ovarian, fallopian tube, or primary peritoneal cancer that has come back and did not respond to previous platinum-based chemotherapy.
- Peritoneal Carcinoma
- Ovarian Cancer
- Fallopian Tube Carcinoma
- Endometrioid Adenocarcinoma
- Peritoneal Adenocarcinoma
- Ovarian Adenocarcinoma
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 3 trial • 154 Patients • NCT02184195Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many people are going to participate in this experiment?
"In order to carry out this clinical trial, 96 individuals who match the given criteria are required. These potential participants can be from various locations, such as University of Oklahoma Health Sciences Center or Women and Infants Hospital."
Are there any current vacancies for participants in this trial?
"The trial is presently recruiting participants, with the most recent update occurring on 9/2/2022. The trial was initially posted on 6/30/2022."
What are the dangers associated with Olaparib treatments?
"While there is some data to support the safety of Olaparib, it only received a score of 2 because there is no evidence yet demonstrating its efficacy."
Share this study with friends
Copy Link
Messenger